Your browser doesn't support javascript.
loading
The target antigen determines the mechanism of acquired resistance to T cell-based therapies.
Martínez-Sabadell, Alex; Morancho, Beatriz; Rius Ruiz, Irene; Román Alonso, Macarena; Ovejero Romero, Pablo; Escorihuela, Marta; Chicote, Irene; Palmer, Hector G; Nonell, Lara; Alemany-Chavarria, Mercè; Klein, Christian; Bacac, Marina; Arribas, Joaquín; Arenas, Enrique J.
Afiliação
  • Martínez-Sabadell A; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain; D
  • Morancho B; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Rius Ruiz I; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain.
  • Román Alonso M; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Ovejero Romero P; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Escorihuela M; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Chicote I; Translational Program, Stem Cells and Cancer Laboratory (VHIO), 08035 Barcelona, Spain.
  • Palmer HG; Translational Program, Stem Cells and Cancer Laboratory (VHIO), 08035 Barcelona, Spain.
  • Nonell L; Bioinformatic Unit (VHIO), 08035 Barcelona, Spain.
  • Alemany-Chavarria M; Bioinformatic Unit (VHIO), 08035 Barcelona, Spain.
  • Klein C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, pRED, Zurich, Switzerland.
  • Bacac M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, pRED, Zurich, Switzerland.
  • Arribas J; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain; D
  • Arenas EJ; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, 08029 Madrid, Spain. Electronic address: earenas@vhio.net.
Cell Rep ; 41(3): 111430, 2022 10 18.
Article em En | MEDLINE | ID: mdl-36261015
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article